NervGen Pharma Corp. Common stock (NGEN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on NervGen Pharma Corp. Common stock (NGEN) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.00 of bullish evidence against -0.36 bearish.

NervGen Pharma Corp. Common stock last closed at $1.81, +1.69% on the session.

Against the IVW growth benchmark the position is +0.77% over the forecast window.

The read is built from 12 underlying insights — 0 bullish and 12 bearish.

Agreement across those insights is 100%.

10 graded predictions for NGEN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks NervGen Pharma Corp. Common stock in the 0th percentile on return on equity, where 100 is best.

NervGen Pharma Corp. Common stock is classified under Health Care / Pharmaceuticals, with a market capitalisation of $191.39M.

StockMap tracks NervGen Pharma Corp. Common stock as the 82nd largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite NervGen Pharma Corp. Common stock ranks 90th of 128 in the group, against a group median of -0.24.